A Phase 2 interventional study of MEDI8897 and Placebo in Respiratory Syncytial Virus Infections, sponsored by MedImmune LLC. Completed at 161 sites in 23 countries. Open to participants aged Up to 365 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-14.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 10th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: Up to 365 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2016.
This study's enrollment of 1,453 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.
This pivotal Phase 2b study will determine if MEDI8897 will be efficacious in reducing medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy preterm infants entering their first RSV season. The population to be enrolled is healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days GA who would not receive RSV prophylaxis. A total of 1500 infants will be randomized 2:1 to receive either MEDI8897 or placebo. Participants will be followed for 360 days after dosing. Enrollment is planned at approximately 197 sites across the USA, Canada, Europe, and the Southern Hemisphere.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
Drug: Placebo
Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
Drug: MEDI8897
A single IM dose of 50 mg on Day 1 of the study.
A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)
The determination of medically attended RSV LRTI is based on objective clinical LRTI criteria and RSV test results obtained from analyzing the respiratory secretions using a validated RSV real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of RSV A or RSV B subtypes. Criteria for LRTI included documented physical exam findings of rhonchi, rales, crackles, or wheeze and any of the following: increased respiratory rate at rest (for age less than (\<) 2 months: greater than or equal to (\>=) 60 breaths/min; 2-6 months: \>= 50 breaths/min; and for \> 6 months - 2 years, \>= 40 breaths/min), or hypoxemia (in room air - oxygen saturation \< 95% at altitudes less than or equal to (\<=) 1800 meters or \< 92% at altitudes \> 1800 meters), or clinical signs of severe respiratory disease or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid).
Time frame: From Day 1 through Day 151
Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)
A RSV hospitalization is defined as either 1) a respiratory hospitalization with a positive RSV test within 2 days of hospitalization (primary) or 2) new onset of respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial).
Time frame: From Day 1 through Day 151
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: From Day 1 through Day 361
Number of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs)
An AESI was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor. An AESI may be serious or non-serious. A NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature. It is observed after receiving study drug and is assessed by investigator as medically significant.
Time frame: From Day 1 through Day 361
Serum Concentration of MEDI8897
Time frame: Days 91, 151, and 361
Elimination Half-life (t1/2) of MEDI8897
Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the serum.
Time frame: Day 91 through Day 361
Number of Participants With Positive Anti-drug Antibodies to MEDI8897
The number of participants with positive serum antibodies to MEDI8897 are reported.
Time frame: Days 91, 151, and 361
The study was conducted from 03-Nov-2016 to 06-Dec-2018.
| Milestone | Placebo | MEDI8897 50 mg |
|---|---|---|
| Started | 484 | 969 |
| Completed | 455 | 913 |
| Not completed | 29 | 56 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Lost to follow-up | 11 | 26 |
| Withdrew: Withdrawal by subject | 11 | 21 |
| Withdrew: Other | 4 | 7 |
The determination of medically attended RSV LRTI is based on objective clinical LRTI criteria and RSV test results obtained from analyzing the respiratory secretions using a validated RSV real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of RSV A or RSV B subtypes. Criteria for LRTI included documented physical exam findings of rhonchi, rales, crackles, or wheeze and any of the following: increased respiratory rate at rest (for age less than (\<) 2 months: greater than or equal to (\>=) 60 breaths/min; 2-6 months: \>= 50 breaths/min; and for \> 6 months - 2 years, \>= 40 breaths/min), or hypoxemia (in room air - oxygen saturation \< 95% at altitudes less than or equal to (\<=) 1800 meters or \< 92% at altitudes \> 1800 meters), or clinical signs of severe respiratory disease or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid).
| Participants | Placebo | MEDI8897 50 mg |
|---|---|---|
| Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI) | 46 | 25 |
A RSV hospitalization is defined as either 1) a respiratory hospitalization with a positive RSV test within 2 days of hospitalization (primary) or 2) new onset of respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial).
| Participants | Placebo | MEDI8897 50 mg |
|---|---|---|
| Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI) | 20 | 8 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Placebo | MEDI8897 50 mg |
|---|---|---|
| TEAEs | 416 | 834 |
| TESAEs | 81 | 108 |
An AESI was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor. An AESI may be serious or non-serious. A NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature. It is observed after receiving study drug and is assessed by investigator as medically significant.
| Participants | Placebo | MEDI8897 50 mg |
|---|---|---|
| AESIs | 3 | 5 |
| NOCDs | 4 | 4 |
| mcg/mL | MEDI8897 50 mg |
|---|---|
| Day 91 | 35.9 ± 10.9 |
| Day 151 | 18.9 ± 7.4 |
| Day 361 | 2.1 ± 1.1 |
Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the serum.
| Days | MEDI8897 50 mg |
|---|---|
| Elimination Half-life (t1/2) of MEDI8897 | 59.3 ± 9.6 |
The number of participants with positive serum antibodies to MEDI8897 are reported.
| Participants | Placebo | MEDI8897 50 mg |
|---|---|---|
| Day 91 | 4 | 11 |
| Day 151 | 6 | 17 |
| Day 361 | 8 | 30 |
Collected over From Day 1 through Day 361. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 3/479 (0.6%) | 81/479 (16.9%) | 402/479 (83.9%) |
| MEDI8897 50 mg | 2/968 (0.2%) | 108/968 (11.2%) | 804/968 (83.1%) |
| Event | Placebo | MEDI8897 50 mg |
|---|---|---|
| BronchiolitisInfections and infestations | 21/479 | 20/968 |
| Lower respiratory tract infectionInfections and infestations | 13/479 | 14/968 |
| BronchitisInfections and infestations | 11/479 | 14/968 |
| PneumoniaInfections and infestations | 10/479 | 13/968 |
| Inguinal herniaGastrointestinal disorders | 6/479 | 1/968 |
| GastroenteritisInfections and infestations | 4/479 | 9/968 |
| Urinary tract infectionInfections and infestations | 4/479 | 0/968 |
| Pneumonia viralInfections and infestations | 2/479 | 7/968 |
| Lower respiratory tract infection viralInfections and infestations | 3/479 | 5/968 |
| Upper respiratory tract infectionInfections and infestations | 3/479 | 3/968 |
| Event | Placebo | MEDI8897 50 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 169/479 | 392/968 |
| NasopharyngitisInfections and infestations | 94/479 | 164/968 |
| PyrexiaGeneral disorders | 63/479 | 109/968 |
| GastroenteritisInfections and infestations | 44/479 | 115/968 |
| RhinitisInfections and infestations | 50/479 | 111/968 |
| DiarrhoeaGastrointestinal disorders | 49/479 | 98/968 |
| BronchitisInfections and infestations | 49/479 | 91/968 |
| Lower respiratory tract infectionInfections and infestations | 46/479 | 75/968 |
| ConjunctivitisInfections and infestations | 39/479 | 86/968 |
| BronchiolitisInfections and infestations | 42/479 | 83/968 |
The intent-to-treat (ITT) population included all participants who were randomized in the study and analyzed according to their randomized treatment group.
| Age, Continuous(Months) | Placebo | MEDI8897 50 mg | Total |
|---|---|---|---|
| Mean | 3.28 ± 2.31 | 3.29 ± 2.22 | 3.29 ± 2.25 |
| Sex: Female, Male(Participants) | Placebo | MEDI8897 50 mg | Total |
|---|---|---|---|
| Female | 224 | 468 | 692 |
| Male | 260 | 501 | 761 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MEDI8897 50 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 91 | 225 | 316 |
| Not Hispanic or Latino | 393 | 743 | 1136 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | MEDI8897 50 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 10 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 3 | 8 | 11 |
| Black or African American | 67 | 189 | 256 |
| White | 355 | 693 | 1048 |
| More than one race | 5 | 12 | 17 |
| Unknown or Not Reported | 43 | 62 | 105 |
Showing the first 100 of 161 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jul 2018, 20 months.
Results were first posted in Oct 2019, 1 year 2 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 20 months is above that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →